美国 · 股市与财经 · The Motley Fool

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

来源：The Motley Fool · 美国 9 小时前

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

在 The Motley Fool 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com)

推荐阅读

Business Insider

I moved my family from Australia to New York City 12 years ago. It's led to some very expensive regrets.

China passenger vehicle retail market slumps 24% in September

Trump says he’s evaluating whether the U.S. should join Saudi Arabia’s fight against Iran-backed Houthi rebels in Yemen after fresh attacks on Riyadh

CFTC Draws the Line Between Prediction Markets and Gambling in New Rules

Petra Power looks to modernize energy for data centers and defense vehicles

Kasai, Klarity and 8 other baby names surging in America